Form 4: Enliven Therapeutics COO Anish Patel Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Anish Patel, COO of Enliven Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 11, 2024, Anish Patel, the Chief Operating Officer of Enliven Therapeutics, exercised options to acquire 14,903 shares of common stock at a price of $2.48 per share.
- Simultaneously, Patel sold 17,500 shares of common stock at a weighted average price of $25.0342 per share, with prices ranging from $25.00 to $25.52.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on June 29, 2023.
- Following these transactions, Patel directly owns no shares and indirectly owns 394,027 shares through The Patel / Dong Family Trust Dated August 24 2017, for which he serves as trustee.
- He also holds options for 60,717 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports transactions. The use of a 10b5-1 plan suggests a planned and orderly approach to selling shares.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to assess management's perspective on the company's value and prospects.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The use of a 10b5-1 trading plan is a common method for insiders to sell shares without raising concerns about trading on non-public information, similar to practices at companies like Pfizer or Amgen where executives routinely use such plans.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- However, the pre-planned nature of the sales mitigates concerns about insider selling based on negative information.
Key Dates
| Date | Description |
|---|---|
| August 24 2017 | Date of The Patel / Dong Family Trust |
| June 29, 2023 | Date of adoption of Rule 10b5-1 trading plan |
| April 11, 2024 | Date of stock option exercise and share sale |
| April 15, 2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.